NCT00147758已完成3 期
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Sulfonylurea Monotherapy or Sulfonylurea Therapy in Combination With Other Oral Anti-Diabetic Agents
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 400
- 试验地点
- 47
- 主要终点
- To assess the additional lowering of HbA1c achieved by addition of colesevelam hydrochloride to current antidiabetic therapy
研究概览
简要总结
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to sulfonylurea alone or in combination with other anti-diabetic drugs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 years, inclusive
- •Diagnosed with type 2 diabetes
- •Stable dose of sulfonylurea alone or in combination with other anti-diabetic medications for 90 days
- •Hemoglobin A1c value 7.5% to 9.5%, inclusive
- •C peptide > 0.5 ng/mL
- •Prescribed ADA diet
排除标准
- •History of type 1 diabetes or ketoacidosis
- •History of pancreatitis
- •Uncontrolled hypertension
- •Allergy or toxic response to colesevelam or any of its components
- •Serum LDL-C < 60 mg/dL
- •Serum TG > 500 mg/dL
- •Body mass index (BMI) > 45 kg/m2
结局指标
主要结局
To assess the additional lowering of HbA1c achieved by addition of colesevelam hydrochloride to current antidiabetic therapy
次要结局
- To assess the fasting plasma glucose and fructosamine lowering efficacy;
- To assess glycemic control response rate;
- To assess the improvement in insulin sensitivity;
- To assess the effect on C reactive protein;
- To assess lipids and lipoproteins;
- To assess the safety and tolerability of colesevelam hydrochloride as add-on therapy
研究者
研究点 (47)
Loading locations...
相似试验
已完成
3 期
WelChol® With Metformin in Treating Patients With Type 2 DiabetesType 2 DiabetesNCT00147719Daiichi Sankyo300
已完成
3 期
PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)GoutNCT00958438Regeneron Pharmaceuticals248
已完成
3 期
PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1Intercritical GoutNCT00829829Regeneron Pharmaceuticals241
已完成
3 期
Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)GoutNCT00856206Regeneron Pharmaceuticals1,315
已完成
2 期
A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety SymptomsMajor Depressive DisorderNCT01582815Janssen Research & Development, LLC121